Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday.

Acton, Massachusetts-based Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people ...

Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and ...

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 ...

Beta Bionics, Inc. (BBNX) is planning to raise $112 million in an initial public offering on Thursday, January 30th, IPO Scoop reports. The company will be issuing 7,500,000 shares at $14.00-$16.00 ...

Underwriters have a 30-day option to purchase extra 1.13 million shares from present owners at IPO price. Beta Bionics will ...

Closed loop insulin pump therapy lowers the risk for hypoglycemic coma but increases diabetic ketoacidosis risk among patients with T1D.

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...

Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...